Research Progress of the Clinical Application of Small Cell Lung Cancer Related Tumor Markers and Biochemical Indicators

© 2021 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

HTML

Abstract

With continual advances in medicine, more studies on early diagnosis, therapeutic evaluation, and prognosis of lung cancer have emerged in recent years, particularly in regard to small cell lung cancer (SCLC), which is a pathological type of lung cancer with the highest grade. In the era of medical treatment scarcity, early diagnosis of SCLC, evaluation of treatment effect, recurrence factors, and prognosis are important to treat patients with SCLC, prolong their survival, and improve their life quality. The research on the changes of serum tumor markers and biochemical indicators in the early diagnosis and treatment of SCLC has gradually become a hot topic. Therefore, this article reviews the research progress of serum tumor markers and biochemical indicators of SCLC.

References

Siegel RL, Miller KD, Fedewa SA, et al., 2017, Colorectal Cancer Statistics. CA Cancer J Clin, 67(3): 177-193.

Xu Y, Liu H, Chen J, et al., 2010, Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009. Thorac Cancer, 1(2): 83-86.

Guo Z, Chen X, 2012, Clinical Significance of NSE in the Diagnosis of Small Cell Lung Cancer. Chinese Medical Science, 2(24): 127-128.

Yin Y, Rong C, Zheng H, 2013, Significance of Pro-GRP and NSE in the Differential Diagnosis of Small Cell Lung Cancer. Journal of Radiation Immunology, 26(3): 312-314.

Petrovic M, Bukumiric Z, Zdravkovic V, et al., 2014, The Prognostic Significance of the Circulating Neuroendocrine Markers Chromogranin A, Pro-Gastrin-Releasing Peptide, and Neuron-Specific Enolase in Patients with Small-Cell Lung Cancer. Med Oncol, 31(2): 823.

Zhou J, 2013, Combined Assay of Gastrin-Releasing Peptide Precursor, Tissue Peptide-Specific Antigen and Neuron-Specific Enolase in the Treatment Monitoring of Patients with Clinical Small Cell Lung Cancer. International Journal of Laboratory Medicine, 34(5): 548-550.

Ren LF, Chen MS, Zhang CP, et al., 2009, Clinical Value of Neuron-Specific Enolase for the Diagnosis of Small Cell Lung Cancer. Modern Medical Oncology, 17(12): 2335-2337.

Planchard D, Le Pechoux C, 2011, Small Cell Lung Cancer: New Clinical Recommendations and Current Status of Biomarker Assessment. Eur J Cancer, 47(3): S272-283.

Hurwitz JL, McCoy F, Scullin P, et al., 2009, New Advances in the Second-Line Treatment of Small Cell Lung Cancer. Oncologist, 14(10): 986-994.

Xu X, Tao M, Xie J, 2011, The Predictive Value of CA125 and CA724 on the Efficacy of GP Regimen Chemotherapy in Advanced Lung Cancer. Journal of Clinical Pulmonology, 16(2): 232-233?

Emin EA, Gundyz A, Batum O, et al., 2010, Pre-Treatment and Treatment-Induced Neuron-Specific Enolase in Patients with Small-Cell Lung Cancer: An Open Prospective Study. Arch Bronconeumol, 46(7): 364-369.

Schneider J, Philipp M, Salewski L, et al., 2003, Pro-Gastrin-Releasing Peptide (Pro-GRP) and Neuron Specific Enolase (NSE) in Therapy Control of Patients with Small-Cell Lung Cancer. Clin Lab, 49(1-2): 35-42.

Wang WL, Zhou CHY, Zhang GY, et al., 2013, Correlation between Pre-Treatment Lactate Dehydrogenase and Neuronal Enolase Levels and Prognosis of Small Cell Lung Cancer. Chinese Journal of Gerontology, 33(10): 2272-2274.

McDonald TJ, Nilsson G, Vagne M, et al., 1978, A Gastrin Releasing Peptide from the Porcine Nonantral Gastric Tissue. Gut, 19(9): 767.

Miyake Y, Kodama T, Yamaguchi K, 1994, Pro-Gastrin-Releasing Peptide (31-98) is a Specific Tumor Marker in Patients with Small Cell Lung Carcinoma. Cancer Res, 54(8): 2136.

Reeve JR Jr, Cuttitta F, Vigna SR, 1988, Processing of Mammalian Pre-Pro-Gastrin-Releasing Peptide. Ann N Y Acad Sci, 547: 21.

Molina R, Filella X, Augé JM, 2004, Pro-GRP: A New Biomarker for Small Cell Lung Cancer. Clin Biochem, 37(7): 505.

Pawel JV, Raith H, Holdenrieder S, et al., 2003, Pro-GRP in Serum Enables Diagnosis of Small Cell Lung Cancer. Lung Cancer, 41(2): 201.

Li Y, Fei Z, 2013, Diagnostic Significance of Four Serum Markers in Small Cell Lung Cancer. Shanghai Preventive Medicine, 25(6): 342-344.

Niho S, Nishiwaki Y, Goto K, et al., 2000, Significance of Pro-Gastrin-Releasing Peptide as a Predictor of Relapse of Small Cell Lung Cancer: Comparative Evaluation with Neuron-Specific Enolase and Carcino-Embryonic Antigen. Lung Cancer, 27(3): 159.

Okusaka T, Eguchi K, Kasai T, et al., 1997, Serum Levels of Pro-Gastrin-Releasing Peptide for Follow-Up of Patients with Small Cell Lung Cancer. Clin Cancer Res, 3(1): 123.

Shibayama T, Ueoka K, Nishii K, et al., 2001, Complementary Roles of Pro-Gastrin-Releasing Peptide (Pro-GRP) and Neuron Specific Enolase (NSE) in Diagnosis and Prognosis of Small-Cell Lung Cancer (SCLC). Lung Cancer, 32(1): 61-69.

Molina R, Auge JM, Alicarte J, et al., 2004, Pro-Gastrin-Releasing Peptide in Patients with Benign and Malignant Diseases. Tumour Biol, 25(1-2): 56.

Inaji H, Komoike Y, Motomura K, et al., 2000, Demonstration and Diagnostic Significance of Pro-Gastrin-Releasing Peptide in Medullary Thyroid Carcinoma. Oncology, 59(2): 122.

Schauenstein E, Lahousen M, Weblacher M, et al., 1996, Selective Decrease in Serum Immunoglobulin G1. A Tissue Nonspecific Tumor Marker Detecting Early Stages of Gynecologic Malignant Disease with High Efficiency. Cancer, 78(3): 511-516.

Xu S, Huo QE, Zhang M, et al., 2020, The Clinical Diagnostic Value of Combined Serum CA153, CEA, SF, CT and Hcy Tests for Breast Cancer. Journal of Molecular Diagnosis and Therapy, 12(2): 190-194.

Chen XK, Gu CL, Fan JQ, et al., 2020, P-STAT3 and IL-17 in Tumor Tissues Enhances the Prognostic Value of CEA and CA125 in Patients with Lung Adeno Carcinoma. Biomed Pharmacother, 125: 109871.

Luo D, Liu Y, Lin S, et al., 2019, Oncogenic Ras/Squamous Cell Carcinoma Antigen Signaling Pathway Activation Promotes Invasiveness and Lymph Node Metastases in Papillary Thyroid Carcinoma. Oncol Rep, 41(2): 1253-1263.

Yang SW, Li SL, Fang X, 2020, Diagnostic Value of CEA, CA125, NSE, and Pro-GRP for Lung Cancer. Medicine and Health Care, 28(3): 135-137.

Hamesch K, Guldiken N, Mahmoud A, et al., 2020, Serum Keratin 19 (CYFRA21-1) Links Ductular Reaction with Portal Hypertension and Outcome of Various Advanced Liver Diseases. BMC Medicine, 18(1).

Hu YH, Cheng SC, Zhang ZG, et al., 2021, Correlation of CYFRA21-1 Gene Polymorphisms with Clinical Features of Lung Cancer. Journal of Clinical Pulmonology, 26(01): 128-131.

Liu HM, Zhang YX, 2020, Changes in Serum CYFRA21-1 and CEA Levels and Clinical Significance in Patients with Non-Small Cell Lung Cancer at Different Clinical Stages. Journal of Mathematical Medicine, 33(05): 674-675.

Bi H, Fang W, Xue Y, et al., Expression and Clinical Application Value of Four Serological Indicators in Lung Cancer Patients. Anhui Medicine, 41(05): 540-543.

Xiong X, Xiong B, Yao F, 2020, The Value of CYFRA21-1 and BTA Stat Detection in the Diagnosis of Bladder Cancer. Med Info, 33(22): 104-106.

Zhang W, Long SQ, Peng YG, 2020, Clinical Evaluation of Combined Serum CYFRA21-1, HCY and CA15-3 Levels for the Adjuvant Diagnosis of Breast Cancer. Journal of Modern Laboratory Medicine, 35(03): 55-57, 61.

Zhang D, Li YQ, Gao Y, et al., 2017, Application Value of TPS, CEA, SCC-Ag and CYFRA21-1 in the Assessment of Head and Neck Tumors. Jiangsu Medicine, 43(01): 68-70.

Cui R, 2005, Analysis of CYFRA21-1 and CEA Test Results in Digestive Tract Malignancies. Modern Medicine, (01): 36-37.

Qin SHF, He HN, 2020, Diagnostic Value Analysis of Pro-GRP, SCC-Ag, and CYFRA21-1 for Small Cell Lung Cancer. Journal of Practical Cancer, 35(11): 1814-1816.

Bu XM, Xia L, Li LW, 2020, The Value of D-Dimer Combined with Tumor Markers in the Diagnosis of Lung Cancer in the Elderly. Clinical and Education in Family Medicine, 18(05): 397-400.

Deng M, Zhao J, 2020, Study on the Correlation between Plasma D-Dimer and Lung Cancer Stage, Pathological Type and Prognosis. Journal of Hebei North College (Natural Science Edition), 36(08): 5-7.

Liu Q, Chen Q, Yue CH, 2020, The Value of Increasing the Critical Value of D-Dimer in Assessing the Prognosis of Lung Cancer Patients. Laboratory Medicine, 35(08): 763-766.

Gao L, Liu B, 2020, Clinical Significance of Plasma D-Dimer Assay in the Assessment of Lung Cancer Chemotherapy. Clinical Significance of Plasma D-Dimer Assay in the Evaluation of Chemotherapy for Lung Cancer. Anhui Medicine, 24(06): 1212-1214.

Feng F, Huang WF, 2013, Modern Clinical Diagnostic Test Book, Sichuan Science and Technology Press, 204.

Liu Y, 2017, Practical Laboratory and Clinical, Heilongjiang Science and Technology Press, 72.

Feng Y, Xiong Y, Qiao T, et al., 2018, Lactate Dehydrogenase A: A Key Player in Carcinogenesis and Potential Target in Cancer Therapy. Cancer Med, 7(12): 6124-6136. doi: 10.1002/cam4.1820

Seth P, Csizmadia E, Hedblom A, et al., 2017, Deletion of Lactate Dehydrogenase-A in Myeloid Cells Triggers Antitumor Immunity. Cancer Res, 77(13): 3632-3643. doi: 10.1158/0008-5472.CAN-16-2938

Ding J, Karp JE, Emadi A, 2017, Elevated Lactate Dehydrogenase (LDH) Can Be a Marker of Immune Suppression in Cancer: Interplay Between Hematologic and Solid Neoplastic Clones and Their Microenvironments. Cancer Biomark, 19(4): 353-363. doi: 10.3233/CBM-160336

Chen F, Zhang F, Zhang XQ, et al., 2020, Analysis of the Role of Serum NSE, Pro-GRP and LDH in the Diagnosis and Treatment of Small Cell Lung Cancer. International Infections Diseases (Electronic Edition), 9(01): 47.

Wang Z, Liu YG, Li XF, et al., 2019, Predictive Analysis of Efficacy and Early Recurrence of Small Cell Lung Cancer After First-Line Treatment. Cancer Progress, 17(24): 2948-2951.

Pan Z, Huang X, Zhang L, et al., 2019, Clinical Significance of Serum Lactate Dehydrogenase Measurement in the First-Line Treatment of Small Cell Lung Cancer. Fujian Journal of Medicine, 41(05): 48-51.

Li ZL, 2013, Progress of Research on the Relationship between Neutrophils, Lymphocytes and Neutrophil-Lymphocyte Ratio and Tumors. Medical Review, 19(17): 3128-3131.

Meng Z, Li P, Yan J, et al., 2014, Relationship between Neutrophil and Lymphocyte Ratios and Tumor Characteristics in Patients with Papillary Thyroid Cancer. Anhui Medicine, 18(10): 1880-1883, 1884.

Yang JW, Wu LL, Ni GNT, 2015, Value of Neutrophil-to-Lymphocyte Ratio in the Prognostic Assessment of Radical Cervical Cancer. Journal of Practical Medicine, 31(16): 2662-2665.

Queen MM, Ryan RE, Holzer RG, et al., 2005, Breast Cancer Cells Stimulate Neutrophils to Produce Oncostatin M: Potential Implications for Tumor Progression. Cancer Res, 65(19): 8896-8904.

Mcdonald B, Spicer J, Giannais B, et al., 2009, Systemic Inflammation Increases Cancer Cell Adhesion to Hepatic Sinusoids by Neutrophil Mediated Mechanisms. Int J Cancer, 125(6): 1298-1305.

Wang Z, Liu YG, Li XF, et al., 2014, Predictive Analysis of Efficacy and Early Recurrence of Small Cell Lung Cancer After First-Line Treatment. Cancer Progress, 36(4): 298-302.

Xu P, Hang C, Liu CY, 2020, Relationship between Peripheral Blood NLR, PLR and Prognosis of Extensive Stage Small Cell Lung Cancer. Traffic Medicine, 34(05): 451-454.

Li W, Chen Z, Zhang B, et al., 2019, Impact of Dynamic Changes in NLR on the Prognosis of SCLC Patients Treated with Chemotherapy. Journal of Practical Oncology, 34(03): 252-256.

Previous article in this issue

Next article in this issue